Drug Information

Product NDC: 0024-5914

Proprietary Name: Dupixent

Non Proprietary Name: Dupilumab

Active Ingredient(s):
  • 300 mg/2mL DUPILUMAB

Administration Route(s): SUBCUTANEOUS


Pharmacy Class(es):
  • Antibodies;
  • Monoclonal [CS];
  • Interleukin 4 Receptor alpha Antagonists [MoA];
  • Interleukin-4 Receptor alpha Antagonist [EPC]

Labeler Information

Labeler Name: sanofi-aventis U.S. LLC
FDA Application Number: BLA761055
Marketing Category: BLA
Start Marketing Date:3/28/2017

Package Information

No. Package Code Package Description Billing Unit
10024-5914-012 SYRINGE, GLASS in 1 CARTON (0024-5914-01) / 2 mL in 1 SYRINGE, GLASS (0024-5914-00)ML
20024-5914-022 SYRINGE, GLASS in 1 CARTON (0024-5914-02) / 2 mL in 1 SYRINGE, GLASS (0024-5914-20)

NDC Record

Field Name Field Value Definition
PRODUCT NDC0024-5914The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEDupixentThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEDupilumabThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEINJECTION, SOLUTIONThe translation of the dosage form Code submitted by the firm.
ROUTE NAMESUBCUTANEOUSThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE3/28/2017This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEBLAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERBLA761055This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEsanofi-aventis U.S. LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEDUPILUMABAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
PHARM CLASSESAntibodies, Monoclonal [CS], Interleukin 4 Receptor alpha Antagonists [MoA], Interleukin-4 Receptor alpha Antagonist [EPC] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023